|

Toripalimab (JS001 ) Clinical Trials

1 actively recruiting trial

Also known as: JS001, toripalimab

Pipeline

Phase 2: 1

Top Sponsors

  • Mabwell (Shanghai) Bioscience Co., Ltd.1

Indications

  • Urothelial Carcinoma of the Renal Pelvis and Ureter1
  • Urothelial Carcinoma Recurrent1
  • Urothelial Carcinoma Bladder1
  • Urothelial Carcinoma1
  • Cancer1

Other1 trial

9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.